chrisvoncsefalvay/vaers-outcomes huggingface dataset:
At 14 hr - (L) arm extremely painful and some numbness of arm and hand. Fever (did not measure). Fatigue. 11/16 and 17 palpation. Today - 11/18 - cont of (L) arm and swollen arm.
patient developed aches and pains a few hours after vaccine that lasted a couple of days. On saturday 7/31 she said she had a pounding heart beat for 4 to 5 hours. side effects have resolved but will follow up with doctor.
Information has been received from a 60 year old female with penicillin allergy and sulfonamide allergy and a history of liver transplant, arthritis and gastrectomy who in  August 2001 was vaccinated with a single dose of VARIVAX (Oka/Merck). Concomitant therapy included anti rejection medication (the name were unspecified). In August 2001, the patient experienced tongue swollen within a couple days of receiving the vaccine. On 31-AUG-2001 the patient was hospitalized and put in isolation and on antibiotics because she had broken out with a case of chicken pox with 20-25 lesions on her body. The patient was released from the hospital on 7-SEP-2001. On 16-SEP-2001 the patient developed an even worse case of chicken pox and herpes zoster and was hospitalized. The lesions were on her left and right side of the stomach, thigh and pubic area. The patient was put back into isolation and put on antibiotics. "A lot of test" and "took pictures" were performed. On 23-SEP-2001 the patient was released from the hospital. On 23-SEP-2001 the patient recovered from chicken pox and herpes zoster. No further information is available.
Back burning; This spontaneous case was reported by a consumer and describes the occurrence of BURNING SENSATION (Back burning) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013LZOA) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced BURNING SENSATION (Back burning). On 02-Feb-2021, BURNING SENSATION (Back burning) outcome was unknown.            Action taken with mRNA-1273 in response to the event was not applicable.  No Concomitant medication were reported.  No treatment medication were reported.   This case was linked to MOD-2021-114659 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2021: Non significant Follow up appended for Doc attachment On 08-Jun-2021: The follow up was received on 08Jun2021 and it contains no new information
muscle pain at the site; Fatigue; headache; upset stomach; muscle pain is now in both arms; It is affecting my life in an extraordinary way; This case was reported by a consumer and described the occurrence of injection site pain in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 4th December 2019, the patient received the 1st dose of Shingrix. On 4th December 2019, immediately after receiving Shingrix and an unknown time after starting ibuprofen, the patient experienced injection site pain, fatigue, headache, upset stomach, muscle pain and loss of personal independence in daily activities. The patient was treated with paracetamol (Tylenol) and ibuprofen. On an unknown date, the outcome of the injection site pain, fatigue, headache, upset stomach, muscle pain and loss of personal independence in daily activities were not recovered/not resolved.   It was unknown if the reporter considered the injection site pain, fatigue, headache, upset stomach, muscle pain and loss of personal independence in daily activities to be related to Shingrix.  Additional details were provided as follows: The age group was not reported but was selected as an adult per the vaccine indication. Immediately following the injection the patient experienced muscle pain at the site, fatigue, headache, upset stomach.  The muscle pain in both arms and continues to the date of reporting. The patient treated with Tylenol or Ibuprofen had no effect on the pain. The patient asked how can he get rid of this pain It was affecting my life in an extraordinary way.  The patient was afraid to get the 2nd dose for fear my symptoms would become worse. The patient asking for recommendation.
Pt. fainted for just a few seconds after the shot and once he gained consciousness he informed us that he could hear everything and apologized for not informing us earlier that he always passes out for less than a minute for any shots due to immense fear of shots. He was absolutely fine in less than a minute and said it wasn't because of vaccines.
developed mucousy, blood streaked diarrhea and tested positive for rotavirus; developed mucousy, blood streaked diarrhea and tested positive for rotavirus; developed mucousy, blood streaked diarrhea and tested positive for rotavirus; This spontaneous report was received from a nurse and refers to a 2-month-old patient. The information about the patient's medical history, drug reaction/ allergies and concomitant therapy was unknown.  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ), orally (dose, lot # and expiration date were not provided) for prophylaxis.  On unknown dates, a few days after the vaccination, the patient developed mucousy, blood streaked diarrhea and tested positive for rotavirus. The outcome of the events was unknown. The causality assessment between the events and the suspect vaccine was not provided.  Upon internal review, the event haematochezia was considered to be medically significant.
Reported "Heart going fast, it might be anxiety". 1400: O2 Sat 99% 65HR 12RR 154/101 1405: 02 99% 68HR 12RR 139/95 1417: O2 99% 66HR 1430: O2 100% 69HR 12RR 129/89 Symptoms began resolving between 1405 and 1430. Afterwards was escorted to work station.
Noted to have maculopapular rash 1 day after Hep B administration on L deltoid area.
1st dose pfizer vaccine was given to patient on 07/08/2021. We found out on 07/09/2021 that vaccine expiration was outside the recommended 31 day expiration window. We reached out to pt on 07/10/2021. Pt  will return to the pharmacy on 07/13/2021 to get be revaccinated.
approximately 10 days to 2 weeks after 2ns vaccine began experiencing severe joint pain to the point of not being able to sleep, swelling in joints, and popping of joints
administered under the deltoid, subcutaneously, instead of in the muscle; administered under the deltoid, subcutaneously, instead of in the muscle,; A spontaneous report (United States) was received from a nurse, who was a 63 year old female patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and it was administered under the deltoid, subcutaneously, instead of in the muscle.  The patient's medical history was not provided. No relevant concomitant medications were reported.   On 19 Jan 2021, the patient received their first of two planned doses of mRNA-1273 (Lot: 013L20A) subcutaneously in left arm for prophylaxis of COVID-19 infection.   On 19 Jan 2021, the patient, who is a nurse, reported that vaccine was administered under the deltoid, subcutaneously, instead of in the muscle. She stated, she gave the injection at a 90-degree angle but below the deltoid. She also mentioned that she showed the manager of the department of health, who went to the supervisor, "they said it should be higher". Treatment information was not provided.   Action taken with mRNA-1273 in response to the event was not reported.  The event, it was administered under the deltoid, subcutaneously, instead of in the muscle, was considered resolved on 19 Jan 2021.; Reporter's Comments: This report refers to a case of 63 yr old female patient who experienced a Product administration error - incorrect route of product administration  for mRNA-1273, lot # 013L20A. There were no reported AEs associated with this case of incorrect route of product administration.
Had them around my eye; the pain in that quarter of my head; This case was reported by a consumer via )interactive digital media and described the occurrence of shingles in a 72-year-old patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced shingles and headache. On an unknown date, the outcome of the shingles and headache were recovered/resolved.   It was unknown if the reporter considered the shingles and headache to be related to Shingles vaccine.  Additional details were reported as follows: This case was reported by the patient for herself/himself. The age at vaccination was not reported. The patient had shingles vaccine and got shingles around eye and the pain in that quarter of head was terrible. The patient had to make several trip to eye doctor to make sure they didn't go into eye this was after having the first shingle shot. The patient also got the second dose
This literature marketed report was received from a healthcare professional via below mentioned literature article refers to 2 pediatric patients of unknown age and gender. Medical history and concurrent conditions were not reported. Loss of anagen hair follicle immune privilege (HFIP) and changes in the ratio of activating to inhibitory natural killer (NK) cells are important in the pathogenesis of alopecia areata (AA). AA had been reported secondary to vaccination, most commonly following administration of the recombinant hepatitis B vaccine. How vaccination might lead to loss of HFIP was unknown. On an unknown date 2 patients were vaccinated with third dose of hepatitis b vaccine (manufacturer unknown) (dose, route of administration and anatomical location was not reported). Concomitant medications were unspecified by reporter. On an unknown date, 2 weeks after the third dose of vaccination, 2 patients experienced alopecia. Potential mechanisms of loss of HFIP following vaccination include increased interferon levels or an antigen-specific T-cell response. An electronic medical record (EMR) database search revealed an increased frequency of AA among those who receive the hepatitis B virus (HBV) vaccine (or 2.7, p<0.0001). An independent analysis revealed an increased frequency of AA in those receiving interferon-beta treatment (or 8.1, p<0.05). In order to explore whether an antigen-specific T-cell response might be elicited by HBV vaccination, a BLAST search was performed of all potential vaccine peptide fragments (6-mers) to look for identical human sequences. 120 human peptides were found to have exact  sequence homology with part of the vaccine. While none of the 120 peptides appeared to be specific to the hair follicle, two of the three longest peptides (8-mers) were from NK cell inhibitory receptors  KIR3DL2 and KIR3DL 1. Software (RANKPEP) designed to predict major histocompatibility complex (MHC) peptide binding demonstrated that, of the 208 potential 9-mers from the vaccine peptide, this KIR peptide is the most likely to bind HLA-DQ1, third most likely to bind HLA-DRB1 11 04 (DR11), fourth most likely to bind HLA-Cw7 02, and one of only 18 predicted binders for HLA-DRB1 0401, all relevant MHC in AA. This suggests that hepatitis B vaccination has the potential to stimulate an immune response against KIR receptors. The outcome of alopecia was unknown. The author considered alopecia to be related to Hepatitis B vaccine. Additional information has been requested.
diarrhea; Vomiting; Arm pain; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (diarrhea), VACCINATION SITE PAIN (Arm pain) and VOMITING (Vomiting) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 018B21A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure abnormal and Cholesterol.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, the patient experienced VACCINATION SITE PAIN (Arm pain). On 17-Apr-2021, the patient experienced DIARRHOEA (diarrhea) and VOMITING (Vomiting). On 24-Mar-2021, VACCINATION SITE PAIN (Arm pain) had resolved. On 19-Apr-2021, DIARRHOEA (diarrhea) had resolved. At the time of the report, VOMITING (Vomiting) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 20-Apr-2021: Patient and other family members experienced diarrhea and vomiting. Patient's daughter went to the hospital and was told it was a stomach bug infection.20-Apr-2021 patient is scheduled for 2nd Moderna  vaccine and wanted to know if it is fine to take 2nd dose of Moderna vaccine with having loose stools.Treatment medication included Pepto Bismol. current condition include cholesterol medication, slow stress pills.
Case number PHEH2014US016826, is an initial spontaneous report received from a pharmacist on 18 Aug 2014. This report refers to a male patient of unknown age. His medical history and concomitant medication was not reported. The pharmacist reported that this pharmacy instructed him to administer vaccinations to patients only with vanishing point syringes. Caller reported that in order to get a full 0.5 ml dose of FLUVIRIN for a patient, pharmacist withdrew the contents of 2 prefilled syringes (PFS) of FLUVIRIN into one vanishing point syringe. The patient was vaccinated with 0.5 ml of FLUVIRIN (batch number: 145303) intramuscularly on 18 Aug 2014. Caller explained that he poked the needle of the Vanishing Point syringe through the PFS tip cap to withdraw enough vaccine from 2 PFS to amount to 0.5 ml on the Vanishing Point syringe. No further information was provided. No adverse event was reported.
Muscle pain at the injection site; This case was reported by a pharmacist via call center representative and described the occurrence of injection site muscle pain in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 31st May 2019, the patient received the 1st dose of Shingrix (intramuscular). On 31st August 2019, the dose was an unknown dose. On an unknown date, less than 4 months after receiving Shingrix, the patient experienced injection site muscle pain. On an unknown date, the outcome of the injection site muscle pain was unknown.   It was unknown if the reporter considered the injection site muscle pain to be related to Shingrix.  Additional details were received as follows: HCP stated that a patient got Shingrix dose 1 in May 2019 and dose 2 in August 2019 (did not provide which day in the months) and experienced muscle pain at the injection site after each injection. The reporter did not consented to follow up.  This case was linked with case US2020053282, reported by the same reporter.
Mother telephoned 12/18/06 at 12N and reported child had a rash all over. On followup call  mom reports child is running a fever and acts like he doesn't feel well. Encouraged to have child evaluated by physician for acute illness vs adverse reaction.
Information has been received from a registered nurse concerning a 4 year old male patient with pervasive developmental disorder (PDD) and mild developmental delay who at the age of 15 months was vaccinated with the first dose of MMR II and on 25-JUN-2010, was vaccinated with the second dose of the vaccine. The nurse reported that on 05-JUL-2010, the patient developed a generalized rash on his body that lasted 3 days. On 29-JUL-2010, the rash reappeared on the patient's legs. The nurse stated that the patient was evaluated at an unspecified emergency room for the rash. The outcome of the patient was not reported. No further information is available.
This spontaneous case, initially received on 02-Nov-2016, was reported by a health professional and concerns a 55 year old patient. Weight: not provided; Height: not provided. Concomitant medication: Not reported. Administration of company suspect drug(s): On 08-Sep-2016, the patient received AFLURIA. Dose regimen: Not reported, Route of administration: Not reported. Batch number: WT53706. No additional suspect drugs. Adverse event description: On 23-Sep-2016, a nurse reported that a refrigerator went in and out of (temperature) range while there was flu vaccine in it. On 08-Sep-2016, doses were administered (special circumstances: drug administration error without adverse event, incorrect product storage). Flu vaccine was first delivered to the vaccination facility on 15-Aug-2016. As the nurse reviewed the refrigerator temperature log, she stated that another excursion occurred on 15-Sep-2016. The doses arrived at 09:00 and were placed in a refrigerator that was at 10 degrees Celsius in the morning. Then the temperature remained at 9 degrees Celsius throughout the 15th and 51 doses were administered on the 16th at a flu clinic. The refrigerator was not back in range until 19-Sep-2016 at a temperature of 8 degrees Celsius. Temperature excursion identified: Log documentation reflected temperature excursions from 31-May-2016 to 23-Sep-2016 which ranged between 8 to 10 degrees Celsius. Vaccines had been given to patients between 31-May-2016 and 23-Sep-2016. The patients will be contacted for revaccination.
2:00 pm patient started shaking uncontrollably and c/o being very cold. Was taken to the emergency room at 4:00 pm and temperature was 104.8. Patient had one episode of vomiting.  Lung Xray  and urine and blood cultures taken and all of them came back negative. IV Antiobiotics and IV fluids given. Patient also received a breathing treatment. Patient recovered by 2 am on October 17th. Discharged home on October 17 at 2:00 pm.
Fever 103, SOB, aches and pains, extreme fatigue, nausea x 3 days  severe arm soreness 1 week
I WOKE UP ON 2/23/2021 TWO WEEKS AFTER MY 2ND  COVID SHOT WITH DIZZINESS, NAUSEA AND LOSS OF HEARING IN MY RIGHT EAR.
A flu vaccine was administered to the patient. It appears a capillary might have been hit upon administration, causing the injection area to swell and form a hard area (filled with blood?).
73 yo F with renal mass was given her second Covid-19 vaccine IM in her right deltoid (lot# EN6206) on 3/4 at 1312.  In the final minutes of this patient's 15 minute observation period, patient was noticed to have pulled her mask down and was looking at the observer as if she wanted to say something.  Observer asked pt if she was ok.  Patient nodded yes. A minute later, the patient dropped her purse and mumbled something.  Patient's arm went up and patient became stiff and started seizing. Observer immediately called for help.  Vitals, glucose and oxygen was placed on patient.  EMS was called.  Provider notified and went to patient who was sitting upright in chair actively having bilateral generalized
rash on her arm; Initial information received on 28-Oct-2019 regarding an unsolicited valid non-serious case received from other health professional.  This case involves female patient of who experienced rash on her arm [Rash], while he/she received vaccine INFLUENZA VACCINE.  The patients past medical history, medical treatment(s), vaccination(s) and family history were not provided.  At the time of the event, the patient had ongoing allergic to Neomycin.   On an unknown date, the patient received dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site.  On an unknown date, the patient developed a non-serious rash on her arm (Rash) Unknown latency following the administration of INFLUENZA VACCINE.  Other relevant tests not reported.  Final diagnosis was rash on her arm.  Information on the batch number was requested.  Corrective treatment antibiotics was received.  The event outcome was reported as unknown for rash on her arm.
Elevated blood pressure, headache (2 days), fever, EXTREME chills/shaking, congestion, loss of appetite, fatigue, could not lift arm.
Patient reported for needed booster but had already received 4 doses as noted when reviewing the chart.  Patient made aware 5th shot is not recommended but he was confused by his doctor referring him to the clinic for another vaccine .  He noted no issues and was called for follow-up.
diarrhea; headache; nausea; chills; fever as high as 101.6; feeling exhausted; Swollen lymph nodes; assumes her body was developing a strong immune response and it was "really bad"; sick; This is a spontaneous report from a contactable Physician. This Physician (patient) reported for herself.  A 64-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: unknown, Expiration date: 31Jul2021), via unspecified route, administered on 09Apr2021 (at the age of 63-year-old) as DOSE 2, SINGLE for COVID-19 immunization. Patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: ER2613, Expiration date: 13Jul2021), via unspecified route, administered on 19Mar2021 (at the age of 63-year-old) as DOSE 1, SINGLE for COVID-19 immunization. Patient experienced shingles, arm pain at the injection site and feeling abnormal after first dose of vaccination. The patient medical history and concomitant medications were not reported. On an 09Apr2021, after the vaccination, the patient experienced side effects and was too sick at the night of vaccination. And on an unspecified date after vaccination, Patient went through heck for 24 hours and assumes her body was developing a strong immune response which was bad. Patient also experienced diarrhoea, headache, Nausea, Swollen lymph nodes, chills and fever as high as 101.6 Fahrenheit and patient was feeling exhausted. fever and chills were observed with the first 1 to 2 days after vaccination. Patient asked about the severity of the second dose and how does that correlate to the third potential booster dose. This is based on assumption that there will be a 3rd dose. She was enquiring about any data that correlated to the severity of symptoms and is there any data that correlates it with a robust immune response. The patient also asked about a booster dose. The patient lab data include body temperature monitoring on an unspecified date with a reading of 101.6 Fahrenheit. The outcome of the event illness was recovered on Apr2021, and outcome other events was unknown.  No follow-up attempts possible. No further information expected.
pt recvd vax 4DEC95 & returned to ofc on 7DEC95 w/constant high pitched cry since vax, able to console for 20-30mins periods only;afeb, still tolerating feeds, no change in stools;fussy
Acute pain and stiffness in right arm, where 2nd vaccination shot was given. Also tinnitus was observed together with loose bowel movements.  Pain treated with Acetaminophen.
Left deltoid rash x 2 d. Rash is "not painful but warm to touch". Patient noticed area of induration & pruritus.
Shortly after vaccine (1-2 weeks?) extreme vertigo noted.  0 illness or other contributing factors noted.  0 changes in lifestyle habits, personal or professional activities, etc.  Vertigo is present daily to varying degrees.  Will seek professional medical attention if condition persists.
difficulty breathing with any exertion, unrelenting ringing/hissing in both ears,  inability to exercise, fatigue, inability to do daily activities not necessary for hygiene and food  headache, sharp intermittent pains (like wasp sting) on right side of body primarily Inability to exercise at pre-booster levels continues with slow improvement over the last month. 3/7/22 did weight training all muscle groups and could manage easily 2 miles on treadmill in 27 minutes at a 4.5 incline, reaching at peak a 140 heart beat. After booster increasingly difficult to climb one flight of stairs, stand long enough to brush teeth. 3 weeks post booster mild exercise possible
pt was hospitalized  Final Diagnosis: Acute renal failure Adm Diagnosis: Acute renal failure & Disease caused by severe acute respiratory syndrome coronavirus 2 (disorder)